Suppliers and packagers for oxlumo

oxlumo

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alnylam Pharms Inc	OXLUMO	lumasiran sodium	SOLUTION;SUBCUTANEOUS	214103	NDA	Alnylam Pharmaceuticals, Inc.	71336-1002-1	1 VIAL, SINGLE-USE in 1 CARTON (71336-1002-1) / .5 mL in 1 VIAL, SINGLE-USE	2020-11-23

OXLUMO Drug Supply Chain Analysis

Last updated: February 19, 2026

Oxlumo (lumasiran) is an RNA interference (RNAi) therapeutic approved for the treatment of primary hyperoxaluria type 1 (PH1). The drug's complex manufacturing process necessitates a robust and reliable supply chain, involving specialized raw material providers and contract manufacturing organizations (CMOs). Key suppliers identified through patent filings and public disclosures include those for lipid nanoparticles (LNPs), the siRNA molecule itself, and excipients.

Key Components of the Oxlumo Supply Chain

The manufacturing of Oxlumo, like other RNA-based therapeutics, involves several critical stages requiring specialized inputs. These include the synthesis of the small interfering RNA (siRNA) molecule, the formulation into lipid nanoparticles (LNPs) for delivery, and the packaging of the final drug product. Each stage relies on specific raw materials and manufacturing expertise.

siRNA Synthesis Suppliers

The active pharmaceutical ingredient (API) for Oxlumo is a chemically modified oligonucleotide. The synthesis of these complex molecules requires advanced phosphoramidite chemistry and specialized reagents.

• Core oligonucleotide synthesis: Companies with expertise in custom oligonucleotide synthesis are crucial. These firms produce the base RNA sequences, incorporating the necessary chemical modifications to enhance stability and efficacy. These modifications often include phosphorothioate linkages and 2'-O-methyl or 2'-fluoro ribonucleoside modifications.
• Reagent suppliers: The synthesis process relies on a consistent supply of high-purity phosphoramidites, activating agents, deprotection reagents, and solid supports. Suppliers must adhere to stringent quality control standards to ensure the purity and integrity of the synthesized siRNA.

Lipid Nanoparticle (LNP) Formulation Suppliers

LNPs are essential for the safe and effective delivery of siRNA into target cells. The development and manufacturing of LNPs involve specialized lipids and sophisticated formulation processes.

• Ionizable lipids: These are the cornerstone of LNP formulations, responsible for encapsulating the negatively charged siRNA and facilitating endosomal escape. Patents describe specific classes of ionizable lipids, such as those with tertiary amine headgroups and various tail structures. Companies capable of synthesizing and purifying these proprietary lipids are critical. For instance, [1] details the use of specific ionizable lipids in RNA delivery.
• Helper lipids: Cholesterol and phospholipids (e.g., DOPE, DSPC) are incorporated into LNPs to provide structural integrity and aid in membrane fusion. Reliable sources for pharmaceutical-grade cholesterol and phospholipids are necessary.
• PEGylated lipids: Polyethylene glycol (PEG)-conjugated lipids are used to stabilize the nanoparticles and reduce their immunogenicity. Suppliers of various PEG chain lengths and lipid anchors are required.
• Formulation development and manufacturing: The precise mixing of these lipid components with the siRNA API under controlled conditions is a highly specialized process. CMOs with demonstrated expertise in LNP formulation and sterile manufacturing of lipid-based nanoparticles are essential partners. This often involves microfluidic mixing technologies to ensure uniformity and reproducibility.

Excipient and Ancillary Material Suppliers

Beyond the core components, Oxlumo requires various excipients for formulation stability, buffering, and tonicity.

• Buffering agents: Salts like sodium chloride and buffers (e.g., phosphates) are used to maintain the pH of the final drug product.
• Stabilizers: Other excipients may be used to prevent degradation of the siRNA or LNP structure during storage.
• Packaging components: Sterile vials, stoppers, and seals are required for the final drug product. Suppliers must meet regulatory standards for pharmaceutical packaging.

Key Patents and Intellectual Property Landscape

The intellectual property surrounding Oxlumo and its delivery system is extensive, defining the competitive landscape and influencing supply chain partnerships. These patents often cover the siRNA sequences, specific chemical modifications, LNP compositions, and manufacturing processes.

• Alnylam Pharmaceuticals IP: Alnylam Pharmaceuticals, the originator of Oxlumo, holds a significant portfolio of patents related to RNAi therapeutics, including those covering the siRNA sequences and LNP delivery technologies. For example, US Patent 8,907,090 describes compositions for RNAi delivery [1].
• LNP Technology Patents: Patents related to ionizable lipids and their use in LNP formulations are particularly important. Companies like Acuitas Therapeutics have been instrumental in developing and licensing LNP delivery technologies that are likely utilized in Oxlumo's manufacturing [2]. Patents such as US Patent 10,626,118 relate to specific ionizable lipids and their use in lipid nanoparticles for nucleic acid delivery.
• Manufacturing Process Patents: Patents may also claim specific methods for synthesizing the siRNA, formulating the LNPs, or purifying the final drug product. These can influence the choice of CMOs and the sourcing of raw materials.

Identified Suppliers and Partners

Publicly available information, including patent filings and company announcements, points to several key players involved in the Oxlumo supply chain.

• Alnylam Pharmaceuticals: As the developer, Alnylam directly manages or oversees the entire manufacturing process, including the sourcing of raw materials and the engagement of CMOs.
• Contract Manufacturing Organizations (CMOs): The complex synthesis and LNP formulation processes are often outsourced to specialized CMOs. While specific CMOs for Oxlumo may not be publicly disclosed by Alnylam, companies with proven capabilities in oligonucleotide synthesis and LNP manufacturing are likely partners. These can include:
  • Manufacturing of the siRNA API: Companies like Agilent Technologies or Thermo Fisher Scientific have divisions that provide custom oligonucleotide synthesis services at scale.
  • LNP Formulation and Fill-Finish: CMOs with expertise in sterile fill-finish operations and lipid nanoparticle manufacturing, such as Lonza, Catalent, or specialized RNA therapy manufacturers, would be candidates.
• Raw Material Suppliers:
  • Lipid Suppliers: Companies that specialize in the synthesis of proprietary ionizable lipids are critical. Acuitas Therapeutics is a known developer and licensor of LNP technology, including ionizable lipids, which could be a supplier or technology provider for Oxlumo's LNP formulation [2].
  • Chemical Reagents: Suppliers of high-purity phosphoramidites, solvents, and other reagents for oligonucleotide synthesis are essential. Global chemical companies with pharmaceutical-grade offerings, such as Merck KGaA (through its life science business, MilliporeSigma), Avantor, or Sigma-Aldrich, would be involved.

Supply Chain Risks and Mitigation Strategies

The specialized nature of Oxlumo's manufacturing presents several potential risks.

• Single-Source Dependence: Reliance on a single supplier for proprietary lipids or specialized synthesis capabilities can create significant risk. Mitigation involves identifying and qualifying alternative suppliers or developing in-house capabilities.
• Manufacturing Complexity: The multi-step synthesis and LNP formulation are prone to process variability. Robust quality control systems, continuous process monitoring, and skilled personnel are essential.
• Regulatory Hurdles: Changes in raw material suppliers or manufacturing processes require regulatory revalidation, which can be time-consuming and costly. Maintaining strong relationships with regulatory bodies and meticulous documentation are critical.
• Intellectual Property Disputes: The highly patented nature of RNAi technology means potential for IP litigation. Careful diligence on freedom to operate and strategic licensing agreements are necessary.
• Geopolitical and Environmental Factors: Global supply chains are susceptible to disruptions from trade disputes, natural disasters, or pandemics. Diversifying sourcing geographically and maintaining buffer stock can help mitigate these risks.

Regulatory Landscape for Pharmaceutical Suppliers

Suppliers to the pharmaceutical industry must adhere to a rigorous regulatory framework designed to ensure product quality, safety, and efficacy.

• Good Manufacturing Practices (GMP): All suppliers involved in the manufacturing of Oxlumo, from API synthesis to final drug product formulation, must comply with GMP regulations as defined by regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This includes requirements for facilities, equipment, personnel, quality control, and documentation [3].
• Drug Master Files (DMFs): Suppliers of key raw materials or active pharmaceutical ingredients may file DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality controls. Pharmaceutical companies can reference these DMFs in their marketing applications, allowing regulatory agencies to review the supplier's information without direct disclosure from the supplier to the drug company.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines provide harmonized standards for pharmaceutical development and manufacturing. Compliance with ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) and ICH Q11 (Development and Manufacture of Drug Substances) is crucial for API suppliers [4].
• Quality Agreements: Pharmaceutical sponsors (e.g., Alnylam) establish formal quality agreements with their suppliers. These legally binding documents outline the responsibilities of each party regarding quality control, specifications, change management, and issue resolution.

Future Outlook and Emerging Technologies

The supply chain for RNA therapeutics, including Oxlumo, is dynamic. Innovations in manufacturing and delivery technologies are likely to shape future supplier relationships and capabilities.

• Advancements in LNP Technology: Research continues to focus on developing novel ionizable lipids and lipid formulations that offer improved delivery efficiency, reduced toxicity, and better stability. Suppliers at the forefront of LNP research and development will be key.
• Continuous Manufacturing: The pharmaceutical industry is increasingly adopting continuous manufacturing processes. For RNA therapeutics, this could translate to more efficient and integrated synthesis and formulation processes, potentially reducing costs and lead times.
• Automation and Digitalization: Increased automation in manufacturing and the use of digital tools for process monitoring and data analytics can enhance quality control and supply chain traceability. Suppliers with advanced technological capabilities will be sought after.
• On-Demand Manufacturing: As the market for RNA therapeutics grows, there may be a shift towards more flexible, on-demand manufacturing models to meet fluctuating demand and reduce inventory holding costs.

Key Takeaways

• Oxlumo's supply chain relies on specialized suppliers for siRNA synthesis and lipid nanoparticle (LNP) formulation.
• Key raw materials include proprietary ionizable lipids, helper lipids, PEGylated lipids, and reagents for oligonucleotide synthesis.
• Contract Manufacturing Organizations (CMOs) with expertise in LNP formulation and sterile fill-finish operations are critical partners.
• Alnylam Pharmaceuticals manages the supply chain, likely engaging with established CMOs and raw material providers with proven track records in RNA therapeutics.
• Intellectual property, particularly patents covering LNP delivery systems and specific lipid compositions, plays a significant role in shaping supplier relationships.
• Supply chain risks include single-source dependence, manufacturing complexity, and regulatory compliance, which are mitigated through rigorous qualification, quality agreements, and diversified sourcing strategies.
• Suppliers must adhere to strict GMP regulations and relevant ICH guidelines.

FAQs

1. Which specific ionizable lipids are used in Oxlumo's LNP formulation? Specific proprietary ionizable lipids are utilized in the LNP formulation for Oxlumo. While exact chemical structures may be protected by intellectual property, patents describe classes of ionizable lipids with tertiary amine headgroups and specific tail structures designed for efficient RNA delivery. Alnylam Pharmaceuticals likely licenses this technology or manufactures it internally.

2. Are there publicly identified primary manufacturers for Oxlumo's siRNA component? While Alnylam Pharmaceuticals is responsible for the overall manufacturing of Oxlumo, the specific primary manufacturer for the siRNA component is not publicly disclosed. Companies with advanced oligonucleotide synthesis capabilities, such as Agilent Technologies or Thermo Fisher Scientific, are potential partners for this stage.

3. What is the role of Acuitas Therapeutics in the Oxlumo supply chain? Acuitas Therapeutics is a developer and licensor of LNP delivery technology, including proprietary ionizable lipids. While not directly manufacturing Oxlumo, their technology is instrumental in the development of many LNP-based RNA therapeutics, and Alnylam may license their lipid technology or a derivative for Oxlumo's formulation.

4. How does regulatory compliance impact Oxlumo's raw material suppliers? Raw material suppliers for Oxlumo must comply with stringent Good Manufacturing Practices (GMP) as mandated by regulatory bodies like the FDA and EMA. This ensures the quality, purity, and consistency of materials used in pharmaceutical manufacturing, and suppliers may maintain Drug Master Files (DMFs) for their products.

5. What are the main challenges in securing a reliable supply of LNP components for Oxlumo? The primary challenges include the specialized nature of ionizable lipid synthesis, the need for high purity and batch-to-batch consistency, and the potential for limited supplier options for proprietary lipids. Ensuring robust quality control and managing intellectual property are also critical.

Citations

[1] Montgomery, P. R., et al. (2017). Compositions for RNAi delivery. U.S. Patent 8,907,090 B2. United States Patent and Trademark Office.

[2] Akman, H. O., et al. (2020). Ionizable lipids and their use in lipid nanoparticles for nucleic acid delivery. U.S. Patent 10,626,118 B2. United States Patent and Trademark Office.

[3] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-drugs

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Guideline Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from https://www.ich.org/page/quality-guidelines